Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA5A | P35218 | 1/20 | 0.51 |
| ▸ | CTSK | P43235 | 13/20 | 0.50 |
| ▸ | CTSS | P25774 | 5/20 | 0.50 |
| ▸ | CTSL | P07711 | 2/20 | 0.50 |
| ▸ | CA1 | P00915 | 1/20 | 0.50 |
| ▸ | CTSB | P07858 | 1/20 | 0.50 |
| ▸ | MMP12 | P39900 | 2/20 | 0.48 |
| ▸ | MMP13 | P45452 | 2/20 | 0.48 |
| ▸ | CAPN1 | P07384 | 2/20 | 0.46 |
| ▸ | CAPN2 | P17655 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7378360 | 0.94 | CA5A (0.46) | CA5ACTSKCTSSCTSLCA1 | |
| SCHEMBL8042541 | 0.88 | CASP1 (0.49) | CA5ACTSKCTSSCTSLCA1 | |
| SCHEMBL5934907 | 0.88 | CA5A (0.52) | CA5ACTSKCTSSCTSLCA1 | |
| SCHEMBL7160684 | 0.87 | CA5A (0.51) | CA5ACTSKCTSSCTSLCA1 | |
| SCHEMBL5934954 | 0.85 | MMP12 (0.49) | CA5ACTSKCTSSCTSLCA1 | |
| SCHEMBL7966128 | 0.83 | CTSK (0.52) | CA5ACTSKCTSSCTSLCA1 | |
| SCHEMBL7160690 | 0.82 | MMP12 (0.49) | CA5ACTSKCTSSCTSLCA1 | |
| SCHEMBL7376478 | 0.81 | PSMB1 (0.47) | CA5ACTSKCTSSCTSLCA1 | |
| SCHEMBL5934909 | 0.81 | CASP1 (0.49) | CA5ACTSKCTSSCTSLCA1 | |
| SCHEMBL7163257 | 0.79 | CTSK (0.46) | CA5ACTSKCTSSCTSLCA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060020001-A1 | Use of cathepsin k inhibitors for the treatment of glaucoma | ALCON, INC. (CH) | 2006-01-26 | — | — | US | claimed |
| WO-2004058238-A1 | USE OF CATHEPSIN K INHIBITORS FOR THE TREATMENT OF GLAUCOMA | ALCON, INC. (CH) | 2004-07-15 | — | — | WO | claimed |
| US-20020173469-A1 | Protease inhibitors | SMITHKLINE BEECHAM CORPORATION | 2002-11-21 | — | — | US | claimed |
| US-20020077455-A1 | Protease inhibitors | SMITHKLINE BEECHAM CORPORATION | 2002-06-20 | — | — | US | claimed |
| US-6057362-A | Protease inhibitors | SMITHKLINE BEECHAM CORPORATION (US) | 2000-05-02 | — | — | US | claimed |
| EP-0934291-A1 | PROTEASE INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 1999-08-11 | — | — | EP | claimed |
| EP-0934291-A4 | — | SMITHKLINE BEECHAM CORP (US) | 1999-08-11 | — | — | EP | claimed |
| WO-1997016433-A1 | PROTEASE INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 1997-05-09 | — | — | WO | claimed |
| US-20060020001-A1 | Use of cathepsin k inhibitors for the treatment of glaucoma | ALCON, INC. (CH) | 2006-01-26 | — | — | US | disclosed |
| WO-2004058238-A1 | USE OF CATHEPSIN K INHIBITORS FOR THE TREATMENT OF GLAUCOMA | ALCON, INC. (CH) | 2004-07-15 | — | — | WO | disclosed |
| US-6586466-B2 | Enzyme inhibitor for use in the treatment of bone, oral, arthritic, paget's and hypercalcemic diseases | SMITHKLINE BEECHAM CORPORATION | 2003-07-01 | — | — | US | disclosed |
| US-6562842-B2 | Osteoporosis, oral diseases | SMITHKLINE BEECHAM CORPORATION | 2003-05-13 | — | — | US | disclosed |
| US-20020173469-A1 | Protease inhibitors | SMITHKLINE BEECHAM CORPORATION | 2002-11-21 | — | — | US | disclosed |
| US-20020077455-A1 | Protease inhibitors | SMITHKLINE BEECHAM CORPORATION | 2002-06-20 | — | — | US | disclosed |
| US-6232342-B1 | CATHEPSIN K INHIBITOR FOR TREATING OSTEOPOROSIS, GINGIVITIS, PERIODONTITIS, ARTHRITIS, OSTEOARTHRITIS RHEUMATOID ARTHRITIS, PAGET'S DISEASE, HYPERCALCEMIA OF MALIGNANCY AND METABOLIC BONE DISEASES | SMITHKLINE BEECHAM CORPORATION | 2001-05-15 | — | — | US | disclosed |
| US-6057362-A | Protease inhibitors | SMITHKLINE BEECHAM CORPORATION (US) | 2000-05-02 | — | — | US | disclosed |
| US-5998470-A | Protease inhibitors | SMITHKLINE BEECHAM CORPORATION (US) | 1999-12-07 | — | — | US | disclosed |
| EP-0934291-A4 | — | SMITHKLINE BEECHAM CORP (US) | 1999-08-11 | — | — | EP | disclosed |
| EP-0934291-A1 | PROTEASE INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 1999-08-11 | — | — | EP | disclosed |
| WO-1997016433-A1 | PROTEASE INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 1997-05-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020173469-A1 | Protease inhibitors | CTSK, CTSZ, CTSG | CA5A 451/4885CTSK 1/4885CTSS 8/4885 |
| US-20020077455-A1 | Protease inhibitors | CTSK, CTSZ, CTSG | CA5A 451/4885CTSK 1/4885CTSS 8/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.